Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Jubilant Life Sciences...

    Jubilant Life Sciences Karnataka plant shut on coronavirus scare

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-04-08T14:15:12+05:30  |  Updated On 8 April 2020 2:15 PM IST
    Jubilant Life Sciences Karnataka plant shut on coronavirus scare

    Mysuru: The drug-making plant of pharma major Jubilant Life Sciences at Nanjangud near here has been shut down after it was suspected to have been infected by a coronavirus from a container that came from China with raw materials, an official said on Tuesday.

    "We have ordered the closure of the plant and sealing of the entire premises after some of its employees tested COVID-19 positive after a virus infected container came from China in March," Mysuru Deputy Commissioner Abhiram G. Sankar told reporters here.

    Nanjangud is about 30 km from Mysuru.

    "We have also quarantined the plant''s staff and their families at their homes while the affected patients are under treatment at a designated hospital in Mysuru," Sankar said.

    Of the 35 COVID cases in Mysuru till Monday, one-third of them are estimated to be the company's employees working at the plant.

    In an e-mail to IANS, the Noida-based pharma company said the integrated plant operations were suspended last week and all its personnel were under self-quarantine.

    "The tainted container has been sent for forensic test to find if its surface material carried the virus as it was shipped from COVID-hit China from where the company imports applied pharmaceutical ingredients (APIs)," Sankar added.

    The decade-old plant has about 1,400 permanent and temporary employees.

    The company got the plant disinfected by a certified agency to make the place safe and healthy.

    "Mysuru has accounted for the second-highest number (35) of COVID positive cases after Bengaluru with 59 out of 175 cases registered in the state till Tuesday noon," a health official said.

    Incidentally, the company donated Rs 25 lakh to the state''s CM Relief Fund, set up to mobilise resources to fight the virus fallout.

    "We value the health and safety of our employees and the community. We are working to ensure their needs are met and following the government protocols to mitigate the crisis," said the company in a statement here.

    The company also distributed 7,000 masks and 325 litres of sanitisers to health and administrative staff in the state.

    Read also: Coronavirus Outbreak: Govt To Grant Licence To Industrial Manufacturers To Produce Oxygen For Medical Use

    jubilant-life-sciencescoronaviruscovid-19api
    Source : IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok